PASCAL Implant
Designed to minimize stress on leaflets and
reduce risk of leaflet tears
For treating mitral and tricuspid regurgitation
Introducing the latest advancement from Edwards Lifesciences in transcatheter mitral and tricuspid therapies
Designed to minimize stress on leaflets and
reduce risk of leaflet tears
Features a narrower design profile to help you optimize your
treatment of mitral and tricuspid regurgitation
Treat your patients with mitral and
tricuspid regurgitation with the latest
transcatheter innovation from Edwards
Lifesciences
Advanced catheter and handle design facilitates smooth navigation and implant deployment¶
Responsive catheter design with optimized torque transfer to facilitate implant placement§
Handle controls engineered for intuitive manipulation, allowing the user to focus on treating the patient¶
*Performance data on file and marketing evaluation.
§Design and performance data on file and marketing evaluation.
¶Design data on file and marketing evaluation.
Maneuver, reconfigure and retract the implant as needed
A wide range of paddle mobility and full elongation capabilities
†Performance data on file.
Enhance leaflet capture with atraumatic reclasp capabilities
Each paddle features a single row of retention elements to clasp, reclasp, and preserve leaflets
Close the implant to conform to native anatomy and flex during the cardiac cycle
‡Performance and simulation data on file.
Deploy the implant with procedural confidence
With an implant designed to adapt to native anatomies and a catheter with balanced flexibility, what you see before release is what you can achieve†
†Performance data on file.
Learn about outcomes from a large randomized trial, early feasibility studies (EFS) and real-world studies
Currently published data from some studies were collected before the availability of the PASCAL Precision delivery system
Prospective, multicenter, randomized controlled trial to directly compare the safety and effectiveness of two contemporary transcatheter edge-to-edge repair (TEER) therapies
aTEE was used for baseline qualification of 5 patients.
Multicenter, prospective, single-arm study (n=124)
Single-center, retrospective analysis from 2017-2020
(PASCAL n=100, MitraClip n=100)
MR = mitral regurgitation.
Deteriorated: reoccurrence of MR due to new jet, increase of residual MR, and/or return of MR
Multicenter, prospective, single-arm study (n=65)
aWilcoxon signed rank test
Retrospective, observational, multicenter study including 524 patients
TR = Tricuspid Regurgitation
*Expert opinions, advice and all other information expressed represent contributors' views and not necessarily those of Edwards Lifesciences
For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable).